Advances in Hidradenitis Suppurativa

Multimedia Medical Education

Supported by an educational grant from AbbVie.*
Medical accuracy confirmed at release date.

Recent Advances in Our Understanding and Management of HS: From Mild to Worsening HS
from Choose Your Own HS Adventure: Going Beyond Current Guidelines
EADV 2019

Thrasyvoulos Tzellos, MD, MSc, PhD
Afsaneh Alavi, MD
Falk G. Bechara, MD
Release Date: 12 November 2019

What Would You Do? Combined Medical and Surgical Approaches in Moderate-to-Severe HS
from Choose Your Own HS Adventure: Going Beyond Current Guidelines
EADV 2019

Thrasyvoulos Tzellos, MD, MSc, PhD
Afsaneh Alavi, MD
Falk G. Bechara, MD
Release Date: 12 November 2019

What Would You Do? Troubling Cases of HS
from Choose Your Own HS Adventure: Going Beyond Current Guidelines
EADV 2019

Thrasyvoulos Tzellos, MD, MSc, PhD
Afsaneh Alavi, MD
Falk G. Bechara, MD
Release Date: 12 November 2019

Ask the Faculty
from Choose Your Own HS Adventure: Going Beyond Current Guidelines
EADV 2019

Thrasyvoulos Tzellos, MD, MSc, PhD
Afsaneh Alavi, MD
Falk G. Bechara, MD
Release Date: 12 November 2019

Modifying the Impact of HS: Lifestyle Considerations
from Ticking All the Boxes: A Multidisciplinary Approach to Hidradenitis Suppurativa
EADV 2018

Thrasyvoulos Tzellos, MD, MSc, PhD
Release Date: 15 October 2018

Addressing the Psychosocial Symptoms of HS
from Ticking All the Boxes: A Multidisciplinary Approach to Hidradenitis Suppurativa
EADV 2018

Errol P. Prens, MD, PhD
Release Date: 15 October 2018

Easing the Pain: Approaches for Clinicians Managing HS
from Ticking All the Boxes: A Multidisciplinary Approach to Hidradenitis Suppurativa
EADV 2018

Falk G. Bechara, MD
Release Date: 15 October 2018

What’s the Goal? Perspectives on What We Want to Achieve for Patients With HS
from Ticking All the Boxes: A Multidisciplinary Approach to Hidradenitis Suppurativa
EADV 2018

Errol P. Prens, MD, PhD
Release Date: 15 October 2018

Faculty Communications

Case Studies, Literature Reviews, and Survey Results

Highlights from the 6th EHSF Conference in 2017

Kelsey R. van Straalen, MD
Hessel H van der Zee, MD

Join the Discussion

Survey Report: How Do Clinicians Approach the Management of Hidradenitis Suppurativa?

Caitriona Ryan, MD

Join the Discussion

Literature Review: Evaluating the Psychological Burden of HS and Its Impact on Relationships and Sexual Function

Hessel H van der Zee, MD, PhD

Join the Discussion

Patient Case Studies

45-year-old man with cyclic Cushing's disease in whom psoriasis vulgaris, an autoimmune-related disease, was ameliorated...

15 year old, female, with complaint of cracks and dryness over sole of both feet with pain for the last 12 and half years...

49-year-old man with erythrodermic psoriasis with arthritis and stage 2 chronic kidney disease presented to the emergency...

In the News

Increased Mortality After MI in Young Adults With Systemic Inflammatory Disease

Myocardial infarctions (MI) in young adults are twice as likely to be fatal in those with inflammatory conditions like psoriasis, lupus, or rheumatoid arthritis, according to results from a study published in the European Journal of Preventive Cardiology. “This suggests that the worse long-term...

AAD Releases First-Ever Guidelines for Treating Paediatric Patients With Psoriasis

The American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) have released guidelines to help ensure that paediatric psoriasis patients receive the best possible treatment and care. The joint AAD/NPF guidelines, published in the Journal of the American Academy of...

Psoriasis Appears Associated With Increased Risk of Developing, Dying of Cancer

Patients with psoriasis appear to have an increased risk of cancer incidence and cancer-related mortality, according to a study published in JAMA Dermatology. For the study, Alex Trafford, University of Manchester, Manchester, United Kingdom, and colleagues searched through 6 electronic databases...

Conference Reports

Efficacy of Upadacitinib for Psoriatic Arthritis Maintained for Up to 56 Weeks

By Erika Powers

VIRTUAL -- June 10, 2021 -- Patients with psoriatic arthritis who were treated with upadacitinib 15 mg or 30 mg maintained responses for over 56 weeks, with rates numerically higher than treatment with adalimumab, according to a study presented at the Virtual 2021 Annual...

Deucravacitinib Effective for Patients With Active Psoriatic Arthritis

By Louise Gagnon

OTTAWA, Ontario -- November 12, 2020 -- Deucravacitinib was effective, compared with placebo, over 16 weeks of treatment in patients with active psoriatic arthritis (PsA), according to a study presented at the 2020 Virtual Meeting of the American College of Rheumatology (...

Tildrakizumab Improves Joint, Skin Manifestations of Psoriatic Arthritis

By Denise Baez

NEW YORK -- November 5, 2020 -- Tildrakizumab improved joint and skin manifestations of psoriatic arthritis better than placebo through 52 weeks, and was well tolerated among patients, according to a study presented at the Virtual 29th Congress of the European Academy of...